Pharmaceuticals, Biotechnology and Life Sciences
45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study1…
Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-upLate-breaking data featured in…
Affluent Medical, a French clinical-stage medical technology company specializing in the international development and industrialization of implantable innovative medical devices, reported a net loss of €9.4 million in H1 2024, compared to a net loss of €8.0 million in the prior year period, citing several majors steps developing its three medical devices.
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified…
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company…
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,…
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024,…
Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate.
Laverock Therapeutics, a UK-based gene-silencing company with a technology for the development of programmable advanced therapies to tackle major diseases,…
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA…